Table 3.
Treatment (N = 15).
| N | Percentage | ||
|---|---|---|---|
| Neoadjuvant Therapy | 10 | 66.7% | |
| Neoadjuvant therapy treatments | CTX alone | 6 | 40.0% |
| RTX alone | 0 | 0.0% | |
| RTX and CTX | 4 | 26.7% | |
| Radiotherapy dose (Gy) | 40–60 | 2 | 13.3% |
| 60–80 | 2 | 13.3% | |
| >80 | 0 | 0.0% | |
| Radiotherapy duration | 1–5 days | 0 | 0.0% |
| 5–7 days | 0 | 0.0% | |
| 7–14 days | 1 | 6.7% | |
| >14 days | 3 | 20.0% | |
| Chemotherapy substances | Platinum based | 8 | 53.5% |
| Immunotherapy | 1 | 6.7% | |
| TKI | 0 | 0.0% | |
| Other | 1 | 6.7% | |
| Cycles applied | 1–3 | 7 | 46.7% |
| 4–6 | 3 | 20.0% | |
| >6 | 0 | 0.0% | |
| Vascular surgery (TEVAR) | |||
| Proximal landing zone | Z0 | 0 | 0% |
| Z1 | 1 | 6.7% | |
| Z2 | 2 | 13.3% | |
| Z3 | 12 | 80% | |
| Z4 | 0 | 0% | |
| Debranching technique and extent | LSA bypass/transposition | 1 | 6.7% |
| LCCA and LSA bypass | 1 | 6.7% | |
| Brachiocephalic trunk, LCCA and LSA bypass | 0 | 0.0% | |
| Laser in situ fenestration LSA | 1 | 6.7% | |
| Parallel graft | 0 | 0.0% | |
| Thoracic tumor resection | |||
| Open approach | Posterolateral thoracotomy | 1 | 6.7% |
| Antero-lateral thoracotomy | 5 | 33.3% | |
| Median sternotomy | 0 | 0.0% | |
| Hemi-clamshell | 3 | 20.0% | |
| Other | 5 | 33.3% | |
CTX—chemotherapy; Gy—gray; LCCA—left common carotid artery; LSA—left subclavian artery; RTX—radiotherapy; TKI—tyrosine kinase inhibitor.